Prothena Co. plc (NASDAQ:PRTA) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 27.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 381,508 shares of the biotechnology company's stock after selling 145,240 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.71% of Prothena worth $5,284,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Virtus ETF Advisers LLC lifted its holdings in Prothena by 19.3% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock worth $71,000 after buying an additional 833 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Prothena by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock worth $158,000 after acquiring an additional 1,065 shares during the period. Rhumbline Advisers increased its position in shares of Prothena by 1.8% during the fourth quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company's stock worth $930,000 after acquiring an additional 1,175 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Prothena by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,269 shares of the biotechnology company's stock valued at $381,000 after acquiring an additional 1,551 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Prothena by 4.0% in the fourth quarter. Invesco Ltd. now owns 42,846 shares of the biotechnology company's stock valued at $593,000 after purchasing an additional 1,632 shares during the period. Hedge funds and other institutional investors own 97.08% of the company's stock.

Analysts Set New Price Targets

PRTA has been the topic of a number of analyst reports. Piper Sandler reduced their price target on Prothena from $110.00 to $81.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 27th. Cantor Fitzgerald lowered shares of Prothena from an "overweight" rating to a "neutral" rating in a research note on Tuesday, May 27th. JMP Securities decreased their price target on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating for the company in a research note on Tuesday, May 27th. HC Wainwright lowered their price target on shares of Prothena from $30.00 to $14.00 and set a "buy" rating for the company in a report on Tuesday, May 27th. Finally, Royal Bank of Canada reduced their price objective on shares of Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $31.50.

Prothena Trading Up 6.9%

PRTA stock traded up $0.35 during trading on Friday, hitting $5.41. 1,250,560 shares of the company's stock were exchanged, compared to its average volume of 706,563. The business has a 50-day moving average price of $8.10 and a two-hundred day moving average price of $12.14. The stock has a market capitalization of $291.20 million, a price-to-earnings ratio of -2.35 and a beta of -0.08. Prothena Co. plc has a 52-week low of $4.32 and a 52-week high of $25.42.

Prothena (NASDAQ:PRTA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The company had revenue of $2.83 million for the quarter, compared to analyst estimates of $8.18 million. During the same period in the previous year, the business posted ($1.34) EPS. The firm's revenue for the quarter was up 5500.0% compared to the same quarter last year. On average, equities research analysts anticipate that Prothena Co. plc will post -4.04 earnings per share for the current fiscal year.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.